Quick Answer
Galmed Pharmaceuticals Ltd. reported Stockholders Equity of $15.78 million for fiscal year 2025.
Galmed Pharmaceuticals Ltd. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $15.78M | -3.3% |
| 2024 | $16.33M | +17.6% |
| 2023 | $13.88M | +3.4% |
| 2022 | $13.42M | -56.0% |
| 2021 | $30.50M | -30.9% |
| 2020 | $44.15M | -36.8% |
| 2019 | $69.85M | -20.5% |
| 2018 | $87.89M | +456.5% |
| 2017 | $15.79M | +42.6% |
| 2016 | $11.07M | -48.6% |
| 2015 | $21.55M | -31.4% |
| 2014 | $31.41M | +1709.8% |
| 2013 | -$1.95M | +1.4% |
| 2012 | -$1.98M | +27.0% |
| 2011 | -$2.71M | — |
- Galmed Pharmaceuticals Ltd. showed a decrease of -3.3% in Stockholders Equity compared to the prior fiscal year.
- Over the 2011–2025 period, Galmed Pharmaceuticals Ltd.’s stockholders equity has grown by 682.4% (from -$2.71 million to $15.78 million).
- The most recent figure is from Galmed Pharmaceuticals Ltd.’s fiscal year 2025 report (Form 20-F), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: